GSA Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
Sell
-2,667
Closed -$295K 2006
2025
Q1
$295K Buy
+2,667
New +$295K 0.03% 1167
2024
Q4
Sell
-8,682
Closed -$1M 1878
2024
Q3
$1M Buy
8,682
+7,078
+441% +$815K 0.08% 471
2024
Q2
$221K Buy
+1,604
New +$221K 0.02% 1424
2023
Q4
Sell
-1,964
Closed -$221K 1768
2023
Q3
$221K Sell
1,964
-482
-20% -$54.2K 0.02% 1240
2023
Q2
$231K Buy
+2,446
New +$231K 0.02% 1190
2023
Q1
Sell
-12,189
Closed -$1.46M 1780
2022
Q4
$1.46M Buy
12,189
+8,386
+221% +$1M 0.18% 75
2022
Q3
$404K Sell
3,803
-1,323
-26% -$141K 0.05% 734
2022
Q2
$500K Buy
+5,126
New +$500K 0.08% 503
2021
Q4
Sell
-4,890
Closed -$469K 1659
2021
Q3
$469K Buy
+4,890
New +$469K 0.05% 734
2020
Q4
Sell
-7,081
Closed -$681K 1474
2020
Q3
$681K Buy
7,081
+5,415
+325% +$521K 0.11% 246
2020
Q2
$203K Buy
+1,666
New +$203K 0.11% 344
2020
Q1
Sell
-14,569
Closed -$1.57M 1379
2019
Q4
$1.57M Buy
14,569
+9,440
+184% +$1.01M 0.18% 59
2019
Q3
$462K Sell
5,129
-4,571
-47% -$412K 0.06% 603
2019
Q2
$819K Buy
9,700
+2,800
+41% +$236K 0.09% 350
2019
Q1
$608K Sell
6,900
-3,500
-34% -$308K 0.06% 575
2018
Q4
$743K Buy
10,400
+5,562
+115% +$397K 0.09% 352
2018
Q3
$595K Buy
+4,838
New +$595K 0.03% 985
2018
Q2
Sell
-2,431
Closed -$202K 1848
2018
Q1
$202K Buy
+2,431
New +$202K 0.01% 1467
2016
Q1
Sell
-5,718
Closed -$323K 1830
2015
Q4
$323K Sell
5,718
-35,648
-86% -$2.01M 0.02% 1422
2015
Q3
$1.65M Buy
41,366
+30,150
+269% +$1.2M 0.08% 359
2015
Q2
$536K Sell
11,216
-96
-0.8% -$4.59K 0.02% 1317
2015
Q1
$449K Buy
+11,312
New +$449K 0.02% 1465
2014
Q3
Sell
-17,211
Closed -$255K 1861
2014
Q2
$255K Buy
+17,211
New +$255K 0.01% 1500